Phase 2 Stroke Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People between 18 and 65 years of age, of any gender
- People who have had their first bleeding episode from a brainstem cavernous malformation (a small, abnormal cluster of blood vessels in the brainstem) within the six months before joining the trial
- People whose brainstem cavernous malformation has been identified as a single lesion through specific types of MRI scans
- People whose bleeding in or around the cavernous malformation has been confirmed by a CT or MRI scan
- People who are able to sign a consent form, with the help and understanding of a guardian if needed
Who may not be able to join:
- People with a history of cancer
- People who are pregnant or breastfeeding
- People who are allergic to sirolimus (a medication) or starch
- People who are in a very severe condition, such as being rated 5 on a standard disability scale, experiencing breathing failure, or currently having serious bleeding that requires life support
- People with abnormal liver or kidney function, or abnormal white blood cell or platelet levels (based on specific blood test results — confirm with trial site)
- People who have previously been treated with medications that suppress the immune system
- People who have previously had surgery on their cavernous malformation
- People who have previously had radiation therapy to the head
- People whose cavernous malformation runs in the family, or who have more than one cavernous malformation
- People who currently have a serious active infection, such as a severe bacterial, viral, or fungal infection
- People with diabetes that is not well controlled
- People who are currently taking part in another clinical trial
- People who are unable or unwilling to have an MRI scan
- People who are currently taking certain medications that affect a specific liver enzyme called CYP3A4, including ketoconazole, voriconazole, itraconazole, telithromycin, or clarithromycin
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Wei Zhu, Doctor, Huashan Hospital
Phone: +8613121226581
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
The primary outcome is to explore the safety of sirolimus in the management of BSCMs.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.